PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes

• Published in: PloS one Vol. 20; no. 2; p. e0305511
• Main Authors: St-Amour, Sophie, Tessier, Laurence, Harnois, Janie, Allard, Catherine, Lavoie, Alexandre, Caron, Philippe, Bouchard, Luigi, Perron, Patrice, Tremblay, Karine
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.02.2025; Public Library of Science (PLoS)
• Subjects: Acidosis; Aged; Analysis; Biology and Life Sciences; Care and treatment; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Dosage and administration; Drug therapy; Enzymes; Female; Genes; Genetic aspects; Genetic variation; Genotype; Genotype & phenotype; Genotypes; Genotyping; Glucose; Homeostasis; Humans; Hypoglycemic agents; Hypoglycemic Agents - therapeutic use; Insulin resistance; Intracellular Signaling Peptides and Proteins - genetics; Kinases; Lifestyles; Linkage disequilibrium; Male; Medicine and Health Sciences; Metformin; Metformin - adverse effects; Metformin - therapeutic use; Methods; Middle Aged; Organic Cation Transporter 2 - genetics; Patient compliance; Pharmacology; Phosphoenolpyruvate Carboxykinase (GTP); Polymorphism, Single Nucleotide; Research and Analysis Methods; Side effects; Type 2 diabetes; Canada

Type 2 diabetes (T2D) is a chronic disorder affecting 462 million worldwide, often managed with metformin as first-line treatment. However, metformin's response varies among individuals, including up to 30% experiencing serious adverse drug reactions (ADRs) and 20-50% inefficacy. These differen...